Global Ultrasound Biopsy Needles Market Strategic Research Report

Scope of the Report

The global Ultrasound Biopsy Needles market size is predicted to grow from US$ 758 million in 2025 to US$ 1,516 million in 2032; it is expected to grow at a CAGR of 10.6% from 2026 to 2032.

Ultrasound biopsy needles are minimally invasive medical devices used under real-time ultrasound, endoscopic ultrasound, or endobronchial ultrasound guidance to collect cells or tissue samples from suspicious lesions, masses, lymph nodes, or organs. These devices are designed for fine-needle aspiration, fine-needle biopsy, core tissue acquisition, or vacuum-assisted biopsy, supporting cytological, histological, molecular, and oncological diagnosis.Ultrasound biopsy needles are usually sold by unit or by set. Pricing varies significantly by product type, including percutaneous core biopsy needles, EUS-FNA/FNB needles, EBUS-TBNA needles and vacuum-assisted biopsy needles. Based on public channel prices and industry research estimates, standard disposable core biopsy needles are generally priced at around USD 20–60/unit; domestic or basic EUS-FNA needles are around USD 80–150/unit; imported EUS-FNA/FNB or EBUS-TBNA needles are commonly priced at USD 150–350/unit; and vacuum-assisted breast biopsy needles may reach USD 300–800/unit or above due to their more complex structure and system compatibility requirements. Actual hospital procurement prices are affected by brand, regulatory approval, purchase volume, tender policy and distributor margins.

The upstream segment mainly includes medical-grade stainless steel tubing, nitinol alloy, needle-tip cutting materials, plastic handles, spring components, puncture sheaths, echogenic coatings, sterile packaging materials and precision processing equipment. The midstream segment covers tube drawing, needle-tip grinding, laser marking, echogenic treatment, handle assembly, sterile packaging, ethylene oxide sterilization and quality inspection. Key barriers include tip sharpness, sampling notch design, smooth needle advancement, ultrasound visibility and batch consistency. Downstream applications include digestive endoscopy, respiratory intervention, breast surgery, thyroid biopsy, liver biopsy, lymph-node biopsy, urology and oncology tissue sampling. End users mainly include hospital endoscopy centers, interventional radiology departments, pathology centers and third-party medical institutions.

Market Drivers

Rising Demand for Early Tumor Screening and Precision Diagnosis

Ultrasound biopsy needles are primarily required for histopathological confirmation of tumors, nodules, lymph nodes and solid lesions. With surging screening volumes for breast cancer, thyroid nodules, liver tumors, pancreatic lesions, lung cancer and gastrointestinal tumors, clinical demand for minimally invasive, real-time image-guided biopsy tools enabling rapid tissue sampling keeps growing. Data from WHO/IARC indicates approximately 20 million new cancer cases worldwide in 2022, and this large diagnostic base directly fuels the expansion of the biopsy needle consumables market.

Upgrading Substitution of High-End Products such as EUS-FNB

In digestive endoscopy and respiratory intervention, EUS-FNA, EUS-FNB and EBUS-TBNA have become vital sampling tools for pancreatic masses, mediastinal lesions, submucosal gastrointestinal lesions and lymph nodes. Compared with conventional fine-needle aspiration needles, FNB needles excel in retrieving intact tissue strips, preserving pathological architecture and supporting molecular testing. Guidelines issued by the American Society for Gastrointestinal Endoscopy (ASGE) recommend FNB needles as the first choice for EUS sampling of solid pancreatic masses, which will drive higher unit prices and penetration rates of high-end biopsy needles.

Accelerated Adoption of Minimally Invasive Diagnosis & Outpatient-Based Workflows

Ultrasound-guided biopsy features real-time localization, minimal trauma, fast patient recovery and relatively manageable operating costs, making it suitable for breast, thyroid, liver, superficial lymph node procedures and partial endoscopic interventions. Hospitals aim to boost sampling efficiency and reduce repeated punctures and inadequate specimens through standardized needles, vacuum-assisted systems and designs with enhanced ultrasound visibility. Next-generation breast biopsy systems are evolving toward compatibility with multi-modal imaging platforms, streamlined workflows and improved operational efficiency.

Market Challenges

High Barriers to Registration, Certification and Clinical Access

Ultrasound biopsy needles are invasive medical consumables that penetrate human tissue, with stringent requirements for sterility, safety, needle tip sharpness, sampling consistency, ultrasound visibility and batch-to-batch uniformity. According to public FDA records, EUS biopsy needle products from Cook, Boston Scientific and other manufacturers must complete corresponding 510(k) submissions or regulatory classification reviews. For new market entrants, product registration, clinical trials, quality system validation and hospital adoption cycles significantly delay commercialization.

Intense Price Pressure and Shrinking Channel Margins

Biopsy needles are high-volume single-use consumables. Hospital procurement prioritizes pricing, stable supply and after-sales support. In markets including China, volume-based centralized procurement for medical consumables continues to streamline distribution layers and squeeze end-market prices, imposing downward cost pressure on both imported and domestic brands. Enterprises lacking large-scale manufacturing capacity, comprehensive registration approvals or direct sales networks face risks of eroded gross profit margins and shrinking market share amid shifting tender policies.

Product Homogenization and Competition from Alternative Technologies

Basic core biopsy needles and standard FNA needles boast mature structures, triggering price competition as domestic manufacturers enter the market. While high-end segments see upgraded offerings including FNB needles, vacuum-assisted biopsy needles and sonographically visible needles, competing sampling technologies vie for market share based on applicable indications and cost trade-offs. For instance, clinical studies reveal discrepancies in diagnostic yield, tissue volume and procedural efficiency across various EUS sampling modalities; hospitals select products according to lesion types, physician preferences and economic considerations.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ultrasound Biopsy Needles market?

What factors are driving Ultrasound Biopsy Needles market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Ultrasound Biopsy Needles market opportunities vary by end market size?

How does Ultrasound Biopsy Needles break out by Type, by End User?

This report presents a comprehensive overview of the global Ultrasound Biopsy Needles market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• EUS-FNA
• EUS-FNB
• Others(EBUS)

Segment by Sampling Method

• Fine Needle Aspiration Needles
• Fine Needle Biopsy Needles
• Core Biopsy Needles
• Vacuum-assisted Biopsy Needles

Segment by Product Structure

• Standard Biopsy Needle
• Automatic / Semi-automatic Biopsy Needle
• Echogenic Biopsy Needle
• Advanced Tissue Acquisition Needle

Segment by Application

• Public Hospitals
• Private Hospitals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Ultrasound Biopsy Needles market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Public Hospitals, Private Hospitals evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact